Johnson & Johnson (JNJ)
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
SciSparc Notification (SPRC)
Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
OraSure to Participate in Upcoming Investor Conference
OneMedNet Reports 815% Bookings Increase and 4.5X increase in Inbound Demand
Adaptimmune Announces Changes to Board and Executive Leadership Team